StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research note released on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
BLPH stock opened at $0.02 on Tuesday. The firm has a 50-day moving average of $0.04 and a two-hundred day moving average of $0.04. Bellerophon Therapeutics has a 12 month low of $0.02 and a 12 month high of $0.10. The company has a market cap of $256,830.00, a price-to-earnings ratio of -0.03 and a beta of 0.74.
Bellerophon Therapeutics Company Profile
See Also
- Five stocks we like better than Bellerophon Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- Transportation Stocks Investing
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
